Forty51 Ventures

Forty51 Ventures is a Basel-based venture capital firm specializing in early-stage biotech investments across Europe. The firm focuses on company formation and early-stage investments in biotech, with a geographic emphasis on Switzerland, France, and Germany. Forty51 Ventures leads or co-leads early rounds (Seed and Series A) of its growing portfolio, which includes both academic and pharma spin-outs.

The firm's investment strategy is therapeutic area agnostic, with a preference for central nervous system (CNS) disorders, oncology, immunology and inflammation, fibrotic disorders, and ophthalmology. Forty51 Ventures aims to be the first institutional investor in biotech companies, supporting entrepreneurs in their journey of venture creation.

Founded in April 2022, Forty51 Ventures closed its first fund, Forty51 Ventures I, in July 2022, raising USD 43 million. The fund is advised by a complementary founding team of industry veterans, including Sara Núñez-García, Sascha Oliver Bucher, and Tamás Schweighoffer, who bring decades of drug development, transactions, and venture expertise. The firm is anchored by a strong institutional investor syndicate with Stable Asset Management and the Fischli Family, among others.